The Food and Drug Administration has revealed that the maker of a brand of eye drops linked to an outbreak of fatal bacterial infections failed to follow multiple safety protocols.
The FDA visited a Global Pharma Healthcare facility in India for an inspection in mid-February and found dozens of issues ranging from dirty equipment and clothing to missing safeguards and procedures.
The inspection came two-and-a-half weeks after the company voluntarily recalled the EzriCare artificial tears product because of possible contamination.
When the recall was issued, there were already 55 reports of adverse events, including eye infections, permanent loss of vision, and at least one death from a bloodstream infection.
Rob Thummel of Tortoise Capital breaks down oil prices, geopolitical risks, and what a volatile energy market could mean for investors and consumers this summer
Paul Dergarabedian, Head of Marketplace Trends for Comscore, joins to discuss Disney earnings, industry leadership shifts and the 2026 box office outlook today.
The new space race isn't about just astronauts, it's about data. Hawkeye 360 CEO John Serafini on satellites, national security, and the company's recent IPO.
Voyager Technologies CEO Dylan Taylor discusses the booming commercial space race, NASA partnerships, defense tech, and building the future beyond Earth.
